Shionogi & Co., Ltd. (4507.T) Stock
Shionogi & Co., Ltd.

Company profile
Shionogi & Co., Ltd. reported revenue of 438.27 billion JPY for fiscal year 2025, up 0.7% from fiscal year 2024, and net income of 170.44 billion JPY. That is a net profit margin of 38.9% for fiscal year 2025. Our analysis of its filings shows revenue growing from 426.68 billion JPY in fiscal year 2023 to 438.27 billion JPY in fiscal year 2025, 1.3% a year on average. Shionogi & Co., Ltd. reports about 6,223 full-time employees.
What stands out
- Its average diluted share count rose 46.6% in fiscal year 2025, from 1.16 billion to 1.70 billion shares.
- The United Kingdom brought in 56% of revenue by region in fiscal year 2025, up from 49% in fiscal year 2024; the company is based in Japan.
- It spent 108.61 billion JPY on research and development in fiscal year 2025, 24.8% of its revenue.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended March 31, 2025.
About Shionogi & Co., Ltd.
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.
Largest shareholders
- Sumitomo Life Insurance Co.6.27%
- Wellington Management Co. LLP3.68%
- Shionogi & Co., Ltd.3.33%
- BlackRock Fund Advisors3.22%
- Sumitomo Mitsui Banking Pension Fund3.20%
Share of the company, as of September 25, 2026
Leadership
- Isao Teshirogi Ph.D. — CEO, President & Representative Director, 66
- John Apeler Keller Ph.D. — Senior Exec. Officer, SVP of R&D Supervisory Unit and Pharma. Tech. Research Div. & Director, 61
- Takeshi Shiota Ph.D. — Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.
- Kazuhiro Hatanaka — Senior Executive Officer & Senior VP of Corporate Supervisory Unit
- Akira Kato Ph.D. — Senior Executive Officer & Senior VP of Supply Supervisory Unit
How much revenue does Shionogi & Co., Ltd. make?
Shionogi & Co., Ltd. reported 438.27 billion JPY in revenue for fiscal year 2025, up 0.7% from 435.08 billion JPY in fiscal year 2024.
Where does Shionogi & Co., Ltd. make most of its revenue?
United Kingdom: 56% of revenue by region in fiscal year 2025, followed by Japan (30%).
How has Shionogi & Co., Ltd.'s revenue by region changed?
Share of revenue by region in fiscal years 2024 and 2025: United Kingdom, 49% and 56%; Japan, 38% and 30%; United States of America, 4% and 5%; Europe, 4% and 5%; Others, 4% and 4%.
How has Shionogi & Co., Ltd.'s revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 297.18 billion JPY; FY2022, 335.14 billion JPY; FY2023, 426.68 billion JPY; FY2024, 435.08 billion JPY; FY2025, 438.27 billion JPY.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Shionogi & Co., Ltd. (4507.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4507.T